BrainStorm Cell Therapeutics Inc. Initiates Stem Cell Safety Study In Primates For Parkinson's Disease
NEW YORK & PETACH TIKVA, Israel--(BUSINESS WIRE)--BrainStorm Cell Therapeutics (OTCBB:BCLI), a leader in Adult Stem Cell Research, announced today that it has initiated a safety trial using an animal model of Parkinson’s disease in primates. The study utilizes BrainStorm’s proprietary adult stem cell technology which has shown efficacy in animal models of Parkinson’s Disease in previous pre-clinical trials. In those studies, human-bone-marrow-derived stem cells were differentiated into astrocyte-like cells (supporting cells) and transplanted into mice and rats brains. The engrafted cells survived, kept their function and significantly improved the motor symptoms of Parkinson's Disease animal models over a long period of time.